 |
 |
Sylvia Berger kindly called our attention to this: http://www.docguide.com/news/content.nsf/news/8D6900B866824A C5852569D2004A496F?OpenDocument&id=223531E8BE5C847A852568DE0 0831550&c=Parkinson%27s&count=10 . It's a nice 'news' article. For a recent discussion of this issue, more 'scientific' than 'news', see the Tanner editorial in JAMA (the Journal of the Medical Association of America [i.e., US]): TANNER CM. Dopamine agonists in early therapy for Parkinson Disease. JAMA October 18,2000; 284 (15): 1971-1973. This reviews all the uncertainties related to the title-issue. Diagnosed some ten months ago, I recently started taking medication. After extensive research, and consultation with my neurologist, I opted for agonist monotherapy and decided to try Permax [pergolide]. After about five weeks, I say: so far, so good. Essentially no ill effects, and there is substantial control of bothersome symptoms. I hope to submit more on this topic in the near future. BTW, it is frequently said that agonist monotherapy for early PD should be considered [only] for younger patients. Nonetheless, I - aged 67 - chose that path and, so far, have no reason to doubt the wisdom of my choice. Ben Winter